Prostate Cancer Clinical Trial

Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies

Summary

The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

completed REDUCE trial (Year 4 exit biopsy with blocks and HE slides available; i.e., U.S. participants only)
compliant with assigned treatment based on either: (dutasteride group) at least 3 post-baseline serum DHT levels ≥ 50% lower than baseline, or (placebo group) at least 3 post-baseline serum DHT levels with none showing ≥ 50% decrease from baseline

Exclusion Criteria:

N/A

Study is for people with:

Prostate Cancer

Estimated Enrollment:

139

Study ID:

NCT01594502

Recruitment Status:

Completed

Sponsor:

University of Illinois at Chicago

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Illinois at Chicago
Chicago Illinois, 60612, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

139

Study ID:

NCT01594502

Recruitment Status:

Completed

Sponsor:


University of Illinois at Chicago

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider